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Objective: To determine the association between systemic medication use and intraocular pressure (IOP) in
a population of older British men and women.
Design: Population-based, cross-sectional study.
Participants: We included 7093 participants from the European Prospective Investigation into Cancere
Norfolk Eye Study. Exclusion criteria were a history of glaucoma therapy (medical, laser, or surgical), IOP
asymmetry between eyes of >5 mmHg, and missing data for any covariables. The mean age of participants was
68 years (range, 48e92) and 56% were women.
Methods: We measured IOP using the Ocular Response Analyzer. Three readings were taken per eye and the
best signal value of the Goldmann-correlated IOP value considered. Participants were asked to bring all their
medications and related documentation to the health examination, and these were recorded by the research nurse
using an electronic case record form. The medication classes examined were angiotensin-converting enzyme in-
hibitors, angiotensin-receptor blockers,a-blockers, b-blockers, calciumchannel blockers, diuretics, nitrates, statins,
insulin, biguanides, sulfonylureas, aspirin, and other nonsteroidal anti-inﬂammatory drugs. We examined associa-
tions between medication use and IOP using multivariable linear regression models adjusted for age, sex, and body
mass index. Models containing diabetic medication were further adjusted for glycosylated hemoglobin levels.
Main Outcome Measures: Mean IOP of the right and left eyes.
Results: Use of systemic b-blockers (0.92 mmHg; 95% CI, 1.19, 0.65; P<0.001) and nitrates (0.63
mmHg; 95% CI, 1.12, 0.14; P ¼ 0.011) were independently associated with lower IOP. The observed asso-
ciations between statin or aspirin use with IOP were no longer signiﬁcant after adjustment for b-blocker use.
Conclusions: This is the ﬁrst population-based study to demonstrate and quantify clinically signiﬁcant dif-
ferences in IOP among participants using systemic b-blockers or nitrates. Lower IOP observed in participants using
statins or aspirin was explained by concurrent systemic b-blocker use. The study ﬁndings may have implications for
the management of glaucoma patients with comorbidity, and may provide insight into the pathophysiologic pro-
cesses underlying IOP. Ophthalmology 2014;121:1501-1507 ª 2014 by the American Academy of Ophthalmology.
This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/3.0/).
Supplemental material is available at www.aaojournal.org.Raised intraocular pressure (IOP) is an important risk factor
for the incidence1 and progression2 of glaucoma. The risk of
developing open-angle glaucoma in a healthy population has
been shown to increase by 16% per 1-mmHg increase in
IOP.1 Little is known regarding the inﬂuence of systemic
medication on IOP, other than for b-blockers.3e5 If a sys-
temic medication does have an inﬂuence on IOP, this may
give insight into the physiologic or pathologic mechanisms
underlying IOP, and may aid the management of glaucoma
patients with systemic comorbidity. Furthermore, for systemic
medications found to have an inﬂuence on glaucoma risk,
such as statins6,7 or calcium channel blockers,8 it would be of
interest to know whether these medications inﬂuence IOP, or 2014 by the American Academy of Ophthalmology
This is an open access article under the CC BY license (http://creativecommons.org/
licenses/by/3.0/). Published by Elsevier Inc.whether their effect on glaucoma risk is largely IOP
independent. To date, no population-based study has sys-
tematically examined the association between common clas-
ses of systemic medication and IOP.
The aim of this study was to examine the association
between the use of common systemic medications and IOP
in a British population.
Methods
Participants
The European Prospective Investigation into Cancer (EPIC) study
is a pan-European prospective cohort study designed to investigate1501http://dx.doi.org/10.1016/j.ophtha.2014.02.009
ISSN 0161-6420/14
Ophthalmology Volume 121, Number 8, August 2014the etiology of major chronic diseases.9 EPIC-Norfolk, one of the
UK arms of EPIC, recruited and examined 25,639 participants aged
40 to 79 between 1993 and 1997 for a baseline examination.10
Recruitment was via general practices in the city of Norwich
and the surrounding small towns and rural areas, and methods
have been described in detail previously.10 Because virtually all
residents in the United Kingdom are registered with a general
practitioner through the National Health Service, general practice
lists serve as population registers. Ophthalmic assessment formed
part of the third health examination and this has been termed the
EPIC-Norfolk Eye Study.11 In total, 8623 participants were seen
for the ophthalmic examination, between 2004 and 2011. The
EPIC-Norfolk Eye Study was carried out following the principles
of the Declaration of Helsinki and the Research Governance
Framework for Health and Social Care. The study was approved by
the Norfolk Local Research Ethics Committee (05/Q0101/191) and
East Norfolk & Waveney NHS Research Governance Committee
(2005EC07L). All participants gave written, informed consent.
Measurements
We measured IOP with a noncontact instrument, the Ocular
Response Analyzer (ORA; Reichert, Corp, Buffalo, NY). The
ORA uses a short (20-ms) pulse of air to indent the cornea and
measure inward and outward applanation pressures using an elec-
trooptical system.12 The average of inward (P1) and outward (P2)
applanation forces has been calibrated to derive a measure
equivalent to IOP measured by Goldmann applanation tonometry;
this is termed Goldmann-correlated IOP.13 In this study, 3 ORA
readings were taken per eye and the best signal value of the
Goldmann-correlated IOP used (based on the best quality pressure
waveform as assessed by the ORA software). Height and weight
were measured with participants wearing light clothing and no
shoes. Height was measured to 0.1 cm using a stadiometer, and
weight was measured to the nearest 0.1 kg using digital scales
(Tanita UK Ltd, Middlesex, UK). Body mass index (BMI) was
calculated as weight/height2. Blood pressure (BP) and heart rate
were measured with the participant seated resting using an objective
measurement device (Accutorr Plus; Datascope Patient Monitoring,
Mindray UK, Ltd, Huntington, UK) on 2 separate occasions during
the health examination and the mean of the 2 measurements
considered. Participants were asked to bring all their medications
and related documentation to the health examination, and these
were recorded by the research nurse using an electronic case record
form.
Statistical Analysis
The classes of medication to be tested were decided a priori, based
on the most common medications taken in the cohort; these were
angiotensin-converting enzyme inhibitors, angiotensin-receptor
blockers, a-blockers, b-blockers, calcium channel blockers, di-
uretics, nitrates, statins, diabetic medication (insulin, biguanides,
and sulfonylureas), aspirin, and nonsteroidal anti-inﬂammatory
drugs excluding aspirin. Lists of the medications in these classes
are provided in Appendix 1 (available at www.aaojournal.org).
The mean IOP of the right and left eyes of each participant was
used for analyses. If data were only available for 1 eye, then the
IOP of that eye was considered for the participant. Participants with
an intereye IOP difference of >5 mmHg were excluded from an-
alyses, because the asymmetry may have been caused by unde-
tected ocular disease or may have been owing to an artifact. We
further excluded participants reporting a history of glaucoma
medication or a glaucoma procedure. Comparisons of IOP in
participants taking medication versus those not taking medication
were undertaken for each class of drug using the independent1502samples t test. To test whether any differences in IOP were inde-
pendent of possible confounders, we used multivariable linear
regression models with IOP as the dependent variable, and medi-
cation, age, gender, and BMI as explanatory variables. Models
containing diabetic medications were further adjusted for blood
glycosylated hemoglobin level. Considering the multiple statistical
tests conducted and the exploratory nature of these analyses, we
highlighted results signiﬁcant at the 5% level after Bonferroni
correction.
Given that many participants were taking >1 class of medica-
tion, we repeated regression analyses further adjusting for a
particular class of drug, 1 at a time, for each drug found to be
signiﬁcantly associated with IOP in the original regression ana-
lyses. We also included all drugs found to be signiﬁcant in indi-
vidual analyses together in 1 multivariable regression model,
adjusted for possible confounders.
To determine whether any association between antihypertensive
medication and IOP was mediated by a change in heart rate or BP,
we repeated regression analyses further adjusted for heart rate, and
systolic BP (SBP) or diastolic BP.
Stata version 12.1 (StataCorp LP, College Station, TX) was
used for all statistical analyses.Results
Of the 8623 participants attending the Eye Study, there were
complete data for IOP and covariables from 7650 participants after
exclusion of participants reporting a history of glaucoma medica-
tion use (n ¼ 276) or a glaucoma procedure (n ¼ 66). After further
excluding participants with an intereye IOP asymmetry of >5
mmHg (n ¼ 557), there were data from 7093 participants (82% of
those attending the Eye Study) that were used for the main ana-
lyses. The mean age of included participants was 68 years (range,
48e92) and 56% were women. Compared with included partici-
pants, excluded participants were signiﬁcantly older (P<0.001),
had higher SBP (P ¼ 0.008), and more were men (P ¼ 0.002).
Included and excluded participants did not have signiﬁcantly
different BMI (P ¼ 0.74) or heart rate (P ¼ 0.29).
Table 1 summarizes the number of participants taking each
class of medication at the time of the health examination, and
provides a comparison of the mean IOP between those taking
and not taking each medication. Participants taking b-blockers
(P<0.001), nitrates (P<0.001), statins (P ¼ 0.002), or aspirin
(P<0.001) had lower IOP on average than participants not taking
each medication. Participants using biguanides or sulfonylureas
had a higher IOP on average than participants not taking the
medication, although there were no signiﬁcant differences after
correction for multiple testing.
After adjustment for possible confounders (age, gender, BMI, and
blood glycosylated hemoglobin level), b-blocker (P<0.001), nitrate
(P<0.001), statin (P ¼ 0.003), and aspirin (P<0.001) use remained
signiﬁcantly associated with lower IOP (Table 2). When these 4
drugs were included in the same multivariable model, only the use
of b-blockers (0.92 mmHg; 95% CI, 1.19 to 0.65; P<0.001)
or nitrates (0.63 mmHg; 95% CI, 1.12 to 0.14; P ¼ 0.011)
remained signiﬁcantly associated with IOP (Fig 1). Further analysis
identiﬁed concurrent use of b-blockers as the explanation for the
single medication associations observed between IOP and statins or
aspirin; these associations lost signiﬁcance when further adjusted
for b-blocker use, but remained signiﬁcant after further adjustment
for nitrate use (Appendix 2; available at www.aaojournal.org).
The magnitude of IOP-lowering associated with systemic b-
blocker or nitrate use was reduced after further adjustment for SBP
or HR, but remained signiﬁcant (Table 3). Results were similar if
adjustment was for diastolic BP rather than SBP (Table 3).
Table 1. Comparison of Mean Intraocular Pressure (IOP) between Participants Taking and Not Taking a Medication, for Different




Mean IOP in Participants
Not Taking Medication (mmHg)
Mean IOP in Participants
Taking Medication (mmHg)
Difference in
IOP (95% CI) P values
ACE inhibitors 1132 15.93 15.86 0.07 (0.29, 0.15) 0.55
Angiotensin receptor blockers 455 15.91 15.98 0.07 (0.26, 0.40) 0.68
a-Blockers 445 15.93 15.70 0.23 (0.56, 0.11) 0.18
b-Blockers 837 16.04 15.01 1.03 (1.28, 0.78) <0.001
Calcium channel blockers 854 15.93 15.78 0.15 (0.40, 0.09) 0.22
Diuretics 1127 15.92 15.89 0.03 (0.25, 0.20) 0.82
Nitrates 224 15.95 14.87 1.08 (1.54, 0.62) <0.001
Statins 1565 15.99 15.67 0.31 (0.51, 0.12) 0.002
Insulin 67 15.92 15.99 0.07 (0.77, 0.91) 0.87
Biguanides 203 15.90 16.44 0.54 (0.05, 1.03) 0.029
Sulfonylureas 125 15.90 16.57 0.67 (0.05, 1.29) 0.033
Aspirin 1282 16.00 15.54 0.46 (0.67, 0.25) <0.001
NSAIDs excluding aspirin 580 15.92 15.90 0.02 (0.32, 0.27) 0.88
ACE ¼ angiotensin-converting enzyme; NSAIDs ¼ nonsteroidal anti-inﬂammatory drugs.
P < 0.0038 appear in boldface, and reﬂect a 5% signiﬁcance level adjusted for multiple comparisons using the Bonferroni correction.
Khawaja et al  Systemic Medication and IOP in the EPIC-Norfolk Eye StudyDiscussion
In this population-based study of older British people, we
found both systemic b-blocker use and nitrate use to be
associated with a lower IOP. The association between statin
or aspirin use and IOP seemed to be explained by the
concurrent use of systemic b-blockers. This study is the ﬁrst
to report the associations of systemic b-blocker or nitrate
use with IOP in a population-based sample.
After the discovery that intravenous propranolol lowered
IOP in the 1960s,3 there have been several studies
demonstrating the ocular hypotensive effect of systemic b-
blockers.4,5,14e19 However, these studies were mostly trials
in small numbers of patients with minimal follow-upTable 2. Results from 13 Multivariable Linear Regression Models
(One for Each Medication) with Intraocular Pressure as the
Dependent Variable
b 95% CI P value
ACE inhibitors 0.03 (0.26, 0.19) 0.76
Angiotensin receptor blockers 0.07 (0.27, 0.40) 0.69
a-Blockers 0.15 (0.49, 0.19) 0.40
b-Blockers 1.04 (1.30, 0.79) <0.001
Calcium channel blockers 0.13 (0.38, 0.13) 0.32
Diuretics 0.03 (0.27, 0.20) 0.77
Nitrates 1.04 (1.51, 0.58) <0.001
Statins 0.29 (0.50, 0.09) 0.003
Insulin 0.34 (1.29, 0.62) 0.49
Biguanides 0.13 (0.46, 0.71) 0.67
Sulfonylureas 0.45 (0.25, 1.16) 0.21
Aspirin 0.42 (0.64, 0.20) <0.001
NSAIDs excluding aspirin 0.05 (0.35, 0.24) 0.72
ACE ¼ angiotensin converting enzyme; NSAIDs ¼ nonsteroidal anti-
inﬂammatory drugs.
All models were adjusted for age, gender, and body mass index. Models for
diabetic medication (insulin, biguanides, and sulfonylureas) were further
adjusted for blood glycosylated hemoglobin level.
P<0.0038 appear in boldface, and reﬂect a 5% signiﬁcance level adjusted
for multiple comparisons using the Bonferroni correction.periods. Oral b-blockers are commonly used in the man-
agement of cardiovascular disorders,20 and 12% of this study
population reported use of oral b-blockers. It would be of
interest to better understand the effect of longer term oral
b-blocker use on IOP at a population level, and to the best
of our knowledge this has not been reported previously.
We found participants using oral b-blockers to have
around 1 mmHg lower IOP than those not using the
medication, independently of age, gender, or BMI. A
difference of 1 mmHg is relatively large on a population
level and, based on 5-year incidence data from the Rotter-
dam Study,1 would translate into a 14% reduced risk of























Figure 1. Regression coefﬁcients with 95% conﬁdence intervals for the
associations between medication classes and intraocular pressure (IOP).
These are results from 1 multivariable regression model containing all
medications shown and further adjusted for age, gender, and body mass
index.
1503
Table 3. Results from 5 Multivariable Linear Regression Models with Intraocular Pressure as the Dependent Variable and Both b-Blocker








for SBP and HR
Further adjusted
for DBP and HR
















0.006 0.50 (0.97, 0.03) 0.038 0.51 (0.98, 0.03) 0.035
DBP ¼ diastolic blood pressure; HR ¼ heart rate; SBP ¼ systolic blood pressure.
All models were adjusted for age, gender, and body mass index with any further adjustment indicated.
Ophthalmology Volume 121, Number 8, August 2014blocker use to be 12% (as in this study) and using incident
glaucoma ﬁgures from another European population1 and
mid-2012 UK population statistics,21 oral b-blocker use
may account for 1022 fewer people aged >55 developing
deﬁnite or probable open-angle glaucoma per year in the
UK. This estimation also assumes that b-blockers have no
other effect on glaucoma other than via IOP. There is evi-
dence in the literature of a protective effect of oral b-blocker
use on the development of glaucoma. In a study examining
data from a UK primary care database, the prevalence of oral
b-blocker use in the 5 years before diagnosis was signiﬁ-
cantly lower in glaucoma patients compared with controls.22
There was also a trend for a reduced risk of incident
glaucoma in participants using oral b-blockers from the
Rotterdam Study (odds ratio, 0.60; 95% CI, 0.30e1.02;
P ¼ 0.06).8
Systemic nitrate medication is a common and established
treatment for chronic stable coronary artery disease.23 The
effect of systemic nitrate use on IOP is not well-
documented, and the evidence in the literature is dated
and conﬂicting. In the ﬁrst half of the 20th century, nitrate
medication was considered to be contraindicated in patients
with glaucoma, in part as a result of early studies demon-
strating an increase of IOP after inhalation of amyl ni-
trate.24,25 Evidence contrary to the belief that nitrates raised
IOP emerged in 1964, when a study of 34 individuals
demonstrated no increase in IOP and often a transient
decrease in IOP after sublingual glyceryl triturate or oral
pentaerythritol tetranitrate.25 In a later study, it was reported
that oral administration of 40 mg isosorbide dinitrate twice
daily resulted in a reduction of IOP lasting for 6 hours in
normal individuals and in patients with open- or closed-
angle glaucoma.24 However, in a more recent masked,
randomized, crossover trial of a single oral dose of
isosorbide mononitrate in 10 healthy volunteers, no
signiﬁcant change in IOP was observed in comparison
with placebo.26 Our study is the ﬁrst to report the
association between nitrate medication use and IOP at a
population level, and to demonstrate that the effect is
statistically independent of changes in BP or heart rate.
We found participants taking nitrate medication to have
around 1 mmHg lower IOP than those not taking the
medication, reducing to around a 0.7-mmHg difference1504after taking oral b-blocker use into account. Again, this
magnitude of IOP-lowering is relatively large on a popula-
tion level, translating to a 10% decreased risk of incident
glaucoma, or 200 fewer people aged >55 years developing
deﬁnite or probable open-angle glaucoma per year in the
UK, based on the assumptions we have detailed herein.
The conﬁdence intervals were wider for the nitrate effect
estimate compared with the b-blocker effect estimate,
likely owing to the fewer number of participants using
nitrates.
Given the known association of IOP with BP and heart
rate,27,28 it is of interest to know how much of the IOP-
lowering associated with an antihypertensive medication is
mediated via a reduced BP or heart rate. We found the IOP-
lowering associated with systemic b-blocker or nitrate use to
reduce by around one-third after adjusting for BP and heart
rate (Table 3). The residual signiﬁcant associations suggest
IOP-lowering mechanisms of b-blockers and nitrates that
are, in part, independent of BP or heart rate.
We did not ﬁnd an association between statin use and
IOP that was independent of oral b-blocker use. In other
words, the lower IOP we observed in participants using
statins was owing to these participants being more likely to
have been using oral b-blockers than participants not taking
statins. Several studies have reported a protective effect of
statins on the development or progression of glau-
coma6,7,29,30; however, none of these studies speciﬁcally
adjusted for systemic b-blocker use. One study adjusted for
overall antihypertensive medication use6 (which may not
sufﬁciently account for the effect of b-blockers) and
another study did not include systemic b-blocker use in
the ﬁnal regression model because it did not attain
signiﬁcance in univariable analysis (although it is not clear
whether there was a signiﬁcant age-adjusted effect, which
would have warranted inclusion in the multivariable
model).30 In 2 other studies, there was no consideration of
systemic b-blocker use.7,29 Therefore, it is possible that
the reported protective association of statins for glaucoma is
owing to confounding by the IOP-lowering effect of con-
current systemic b-blocker use. Alternatively, statins may
exert a protective effect via IOP-independent mechanisms,
such as neuroprotection of retinal ganglion cells by
decreasing glutamate-mediated cytotoxicity.31
Khawaja et al  Systemic Medication and IOP in the EPIC-Norfolk Eye StudyWe did not ﬁnd an association between aspirin use and
IOP that was independent of oral b-blocker use. This is in
keeping with the results of a randomized, crossover trial of
aspirin versus placebo32 and also in agreement with results
from the Rotterdam Study, which reported that use of
anticoagulants or platelet aggregation inhibitors was not
associated with incident open-angle glaucoma.33 The
Rotterdam Study did report a nonsigniﬁcant trend towards
lower IOP in participants taking aspirin (0.21 mmHg;
95% CI, 0.44 to 0.01), although this was not adjusted
for concurrent oral b-blocker use.33
There are several implications of the results of our study.
It is important to consider systemic medication when
assessing patients with glaucoma or suspected glaucoma. An
individual using a systemic b-blocker or nitrate may have
had higher IOP for many years before the commencement of
their systemic medication. Similarly, commencement or
cessation of systemic medication may have implications for
the management of an established glaucoma patient, result-
ing in an increased or decreased requirement for IOP-
lowering.
Another consideration concerns the dual prescribing of oral
and topical b-blockers. The majority of the observed associa-
tionoforalb-blocker use and IOP inour studywas independent
of SBP and heart rate, and is likely to have been via the same
mechanism as topical b-blockers. Furthermore, topical b-
blockers are well-absorbed systemically via the nasal mucosa
and via pulmonary absorption of inhaled drug particles,
avoidingﬁrst-passmetabolism in the liver and resulting in high
plasma levels of the drug.34 It follows that the IOP-lowering
effect of topical b-blockers may be blunted in patients
already using oral b-blockers, while increasing the chance of
systemic side effects. Data from a combination of 2 random-
ized trials suggest that systemic b-blocker therapy reduces the
effect of topical timolol.35 Sublingual timolol has been shown
to be almost as effective as topical timolol in a randomized,
crossover study of 12 patients with ocular hypertension.14
Contrary evidence comes from a study of 30 patients with
systemic hypertension treated by oral b-blockers, which
demonstrated further reduction of IOP after additional topical
instillation of timolol in all patients.36 Either way, it has been
suggested that concurrent prescription of oral and topical b-
blockers is not optimal practice.37
It is also important to consider the effect of systemic
medication on the risk for glaucoma, rather than just the
effect on IOP. Although lowering the IOP would likely
reduce the risk of glaucoma, the reduction in BP that occurs
with b-blockers and nitrates may reduce perfusion to the
optic nerve, which may in turn increase the risk of glau-
coma. Certainly, lower BP has been associated with an
increased prevalence38,39 and incidence40 of open-angle
glaucoma in population-based studies.
The possible IOP-lowering effect of nitrate medication
has not been discussed in depth in the literature and may
not be well-known in clinical practice. Understanding how
nitrates might lower IOP may provide insight into the
pathophysiologic processes that underlie IOP and ocular
hypertension, and could potentially lead to new therapies.
Metabolic transformation of nitrate moieties in nitratemedications results in nitric oxide formation.41 Nitric
oxide is an important mediator of ocular homeostatic
processes, including the regulation of aqueous ﬂow, and
potential sites for action include the trabecular
meshwork and ciliary body.42e45 It is conceivable that
nitrates administered topically may be a means of lowering
IOP. In a masked, randomized trial of topical isosorbide
mononitrate drops in 10 patients with glaucoma or ocular
hypertension, there were no changes in IOP or aqueous
ﬂow compared with placebo.46 However, in a more recent
study in rabbits with carbomer-induced glaucoma, topical
isosorbide mononitrate did lower IOP compared with
vehicle, albeit to a lesser degree than topical dorzola-
mide.47 Latanoprostene is a topical nitric oxide-donating
prostaglandin F2a analog currently undergoing a phase 3
trial in patients with open-angle glaucoma or ocular hy-
pertension (registered at www.clinicaltrials.gov; identiﬁer
NCT01895972).
The strengths of this study include the population-based
design and the large sample size. Given the smaller numbers
of participants taking nitrate medications, the effect may not
have been apparent in a smaller sample. There are some
limitations of this study. The sample, although population
based, was likely to have been healthier than the general
population given the nature of the study, which required
travel to the research clinic. Furthermore, participants we
excluded from the analyses were known to be older, with
higher SBP, and more were men, compared with those
included in the analyses. The effect of excluding these
participants would be to reduce power to detect associations
unless the direction of association in the excluded partici-
pants was opposite to the direction in included participants,
which is unlikely. Although it seems reasonable to assume
the associations seen would apply in glaucoma patients as
well, we cannot make this assertion given that the partici-
pants were largely free of ocular disease. We measured IOP
at only 1 time point, and we were therefore unable to
determine whether systemic medication was associated with
other attributes of IOP, such as diurnal ﬂuctuation or peak
IOP. The observational and cross-sectional design of the
study limits any causal inference from our ﬁndings. For
example, the observed associations might be inﬂuenced by
unmeasured confounders.
In conclusion, we found systemic b-blocker and nitrate
use to be associated with lower IOP in a population of older
British men and women. The ﬁndings may have implications
for the management of glaucoma patients with comorbidity,
and may provide insight into the pathophysiological pro-
cesses underlying IOP.References
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